Mounjaro vs Retatrutide: Head-to-Head Efficacy Compared

Why a Direct Comparison Does Not Exist Yet

No randomized trial has placed tirzepatide and retatrutide in the same study against each other. Cross-trial comparisons are the only available method, and they carry real limitations that clinicians should weigh before drawing conclusions.

Retatrutide entered clinical development later than tirzepatide. Eli Lilly's Phase 2 trial for retatrutide (Jastreboff et al., NEJM 2023) enrolled 338 adults with obesity and reported results over 48 weeks [2]. Tirzepatide's key obesity data came from the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), which enrolled 2,539 participants and ran for 72 weeks [3]. Different trial durations, different baseline BMIs (averaging 37.3 in SURMOUNT-1 vs. 37.3 in the retatrutide Phase 2), and different dose-escalation schedules make any numerical comparison imprecise. The Lilly TRIUMPH Phase 3 program for retatrutide is underway. That program may eventually include an active comparator arm, but no head-to-head data against tirzepatide has been announced.

Cross-trial comparisons remain hypothesis-generating. They are not substitutes for randomized evidence.

How the Mechanisms Differ

Tirzepatide activates two incretin receptors: GLP-1 and GIP. Retatrutide activates three: GLP-1, GIP, and the glucagon receptor. That third target is what separates the two drugs pharmacologically.

The glucagon receptor activation in retatrutide increases hepatic energy expenditure and promotes lipid oxidation in preclinical and early clinical data [2]. GLP-1 agonism suppresses appetite and slows gastric emptying. GIP agonism appears to amplify the GLP-1 effect on insulin secretion and may independently affect fat tissue metabolism, as demonstrated in tirzepatide's development program [1]. The triple-agonist approach theoretically pushes weight loss further by adding caloric expenditure on top of appetite suppression. Whether that theoretical advantage translates into a clinically meaningful difference over tirzepatide is the central question that Phase 3 data will need to answer.

Both drugs are manufactured by Eli Lilly. Both are subcutaneous injectables administered once weekly.

Weight Loss: Cross-Trial Numbers

The highest reported weight-loss figures from each drug's clinical program represent the most common comparison point. Context matters here, and the numbers require careful reading.

In SURMOUNT-1, tirzepatide 15 mg produced 22.5% mean body-weight reduction at 72 weeks in adults with obesity (BMI ≥30) or overweight (BMI ≥27 with at least one comorbidity) without diabetes [3]. The 10 mg dose produced 19.5%, and the 5 mg dose produced 15.0% [3]. These are treatment-policy estimates, meaning they include participants who discontinued the drug.

In the retatrutide Phase 2 trial, the 12 mg dose (4 mg starting, escalated monthly) produced 24.2% mean body-weight loss at 48 weeks [2]. The 8 mg dose produced 22.8%, and the 4 mg dose produced 17.1% [2]. Weight loss curves at 48 weeks had not yet plateaued, suggesting that longer treatment duration could yield even greater reductions.

A simple side-by-side read of 24.2% (retatrutide at 48 weeks) vs. 22.5% (tirzepatide at 72 weeks) appears to favor retatrutide. The shorter trial duration for retatrutide makes this comparison more striking. But Phase 2 trials enroll fewer, more carefully selected participants, and effect sizes often attenuate in larger Phase 3 populations. The SURMOUNT program enrolled over 5,000 participants across four Phase 3 trials, and the weight-loss results held up. Whether retatrutide's numbers survive that same scaling remains to be seen.

Glycemic Control: A1C Reductions

Both drugs were tested in populations with type 2 diabetes (T2D), though the trial designs differ significantly.

SURPASS-2 compared tirzepatide (5 mg, 10 mg, 15 mg) against semaglutide 1 mg in 1,879 adults with T2D over 40 weeks. Tirzepatide 15 mg reduced A1C by 2.37 percentage points vs. 1.86 for semaglutide 1 mg. All three tirzepatide doses met superiority against semaglutide [1]. The proportion of participants reaching A1C <7% was 92% for tirzepatide 15 mg vs. 81% for semaglutide. The proportion reaching A1C <5.7% (non-diabetic range) was 51% for tirzepatide 15 mg vs. 20% for semaglutide [1].

The retatrutide Phase 2 trial included a T2D subcohort (n=210). At 12 mg, A1C dropped by 2.02 percentage points from a baseline of 8.3% over 24 weeks [2]. The glycemic data for retatrutide used a shorter observation period (24 weeks vs. 40 weeks in SURPASS-2) and a smaller sample. Tirzepatide's A1C reductions in SURPASS-2 were measured against an active comparator (semaglutide), while retatrutide's were measured against placebo.

Comparing raw A1C reductions (2.37% vs. 2.02%) without adjusting for baseline A1C, trial duration, and comparator type is not methodologically sound. Both drugs show potent glycemic effects, but tirzepatide has substantially more Phase 3 evidence to support its T2D profile. The American Diabetes Association (ADA) 2024 Standards of Care list tirzepatide as a recommended option for T2D with obesity [4].

Safety and Tolerability Profiles

Gastrointestinal side effects dominate both drug profiles. Nausea, vomiting, diarrhea, and constipation are the most common adverse events for both tirzepatide and retatrutide, consistent with the GLP-1 receptor agonist drug class [3].

In SURMOUNT-1, nausea occurred in 24.6% of tirzepatide 5 mg participants, 33.3% at 10 mg, and 31.0% at 15 mg. Diarrhea rates ranged from 18.7% to 21.1% across doses [3]. Most GI events were mild to moderate and concentrated during the dose-escalation phase. Discontinuation due to adverse events was 4.3% to 7.1% across tirzepatide doses [3].

In the retatrutide Phase 2 trial, GI adverse events increased with dose. At 12 mg, nausea occurred in approximately 25%, diarrhea in 22%, and vomiting in 13% of participants [2]. Discontinuation rates due to adverse events were 6% at 8 mg and 16% at 12 mg [2]. The higher discontinuation rate at the 12 mg dose is notable and may influence dose selection in Phase 3.

Retatrutide's glucagon receptor activation raises theoretical questions about hepatic safety that GLP-1/GIP-only agonists do not face. Phase 2 data showed increases in heart rate (2 to 5 bpm above placebo) consistent with the GLP-1 class, and no clinically significant liver enzyme elevations were reported [2]. Phase 3 data on hepatic outcomes will be important for the drug's regulatory path.

Approval Status and Availability

This distinction matters more than efficacy numbers for anyone considering treatment today. Tirzepatide is FDA-approved and commercially available. Retatrutide is not.

Tirzepatide received FDA approval for T2D as Mounjaro in May 2022 and for chronic weight management as Zepbound in November 2023 [5]. It is covered by many commercial insurers for the T2D indication, though coverage for obesity varies widely. The Endocrine Society clinical practice guideline (2024) for pharmacological treatment of obesity includes tirzepatide as a first-line option for adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities [6].

Retatrutide is in Phase 3 development under Eli Lilly's TRIUMPH clinical trial program. The earliest possible FDA approval, assuming positive Phase 3 results and standard review timelines, is unlikely before late 2026 or 2027. The drug is not available through any legal prescription pathway outside of clinical trials. Compounding pharmacies cannot legally produce retatrutide, and any products marketed as retatrutide outside of Lilly's supply chain carry unknown safety risks [7].

Which Patients Might Benefit from Each

For patients who need treatment now, tirzepatide is the relevant option. It has demonstrated efficacy across four Phase 3 obesity trials (SURMOUNT-1 through SURMOUNT-4) and five Phase 3 T2D trials (SURPASS-1 through SURPASS-5) [1].

Retatrutide's clinical profile, if confirmed in Phase 3, may eventually offer advantages for specific populations. The glucagon-receptor component's effect on hepatic lipid metabolism could be particularly relevant for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) [2]. In the Phase 2 trial, liver fat reductions with retatrutide were substantial, though dedicated MASLD trials have not yet reported. Patients with the highest BMIs (≥40) might also benefit from the additional weight-loss magnitude that triple agonism appears to deliver, assuming Phase 3 data confirms the Phase 2 signal.

The choice between these two drugs will become clinically relevant only after retatrutide receives regulatory approval. Until then, tirzepatide remains the only GIP-inclusive incretin therapy with FDA authorization.

What the Phase 3 TRIUMPH Program Will Clarify

Several open questions about retatrutide can only be answered by the TRIUMPH Phase 3 program, which includes multiple trials across obesity, T2D, and related metabolic conditions.

Key questions include whether the 24.2% weight loss at 48 weeks replicates in a larger population, what the optimal dose and escalation schedule will be for balancing efficacy with GI tolerability, and whether the drug's effect on liver fat translates into clinical outcomes for MASLD. The program is also expected to generate cardiovascular outcomes data. Tirzepatide's cardiovascular data from the SURPASS-CVOT trial (reported in 2024) showed a reduction in major adverse cardiovascular events in T2D patients with established cardiovascular disease, as published in The Lancet [8]. Whether retatrutide offers comparable or superior cardioprotection is unknown.

Lilly has not disclosed whether any TRIUMPH trial includes a tirzepatide comparator arm. If one does, it would provide the first true head-to-head efficacy and safety comparison between these agents.

Clinical Bottom Line

Prescribing decisions today involve tirzepatide, not retatrutide. For patients already on tirzepatide with suboptimal weight-loss response (defined by the Endocrine Society as <5% weight loss at 3 months on a maximally tolerated dose), the current options include switching to semaglutide 2.4 mg or adding adjunctive therapies [6]. Retatrutide may become a switching option in the future. Clinicians should watch for TRIUMPH Phase 3 readouts, expected between late 2026 and 2028, before drawing conclusions about retatrutide's place in the treatment algorithm.